More about the combination of rituximab, cyclosporine and dexamethasone in the treatment of chronic ITP. A useful option on an environment with limited resources.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Thabet AF;Thabet AF; Moeen SM; Moeen SM
  • Source:
    Platelets [Platelets] 2020 Aug 17; Vol. 31 (6), pp. 784-787. Date of Electronic Publication: 2019 Oct 11.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 9208117 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1369-1635 (Electronic) Linking ISSN: 09537104 NLM ISO Abbreviation: Platelets Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: Edinburgh ; New York : Churchill Livingstone, c1990-
    • Subject Terms:
    • Abstract:
      Treatment of chronic primary immune thrombocytopenia (ITP) is challenging especially with limited resources and therapy-related complications. This prospective interventional study assessed the efficacy and safety of triple therapy(TT4); a combination treatment of oral dexamethasone 40 mg for days1-4, oral cyclosporine A 2-3 mg/kg daily for 28 consecutive days and intravenous rituximab 100 mg for days7,14,21 and 28 among 40 patients with ITP who failed previous 2 or more treatment options. Our aim was to maintain platelet count ≥ 30 X 10 9 /L without any obvious bleeding at any point in the study. Platelet counts were assessed weekly for a month then monthly for 2 years to evaluate the long-term response. TT4 was well tolerated and induced a good response with a significant increase in the mean platelet count after the 1 st , 2 nd , 3 rd , and 4 th week compared to the baseline. Patients with mean platelet count ≥ 30 X 10 9 /L at the 6 th month were 75% (30/40 patients). Treatment free survivals (TFS) at 12 and 24 months were 93.3% (28/30 patients) and 80% (24/30 patients) respectively. TT4 is an effective treatment option that maintained platelet count in the desired level and induced a higher sustained response, especially in an environment with limited resources.
    • Contributed Indexing:
      Keywords: Bleeding; Platelet; immune thrombocytopenia; triple therapy
    • Accession Number:
      4F4X42SYQ6 (Rituximab)
      7S5I7G3JQL (Dexamethasone)
      83HN0GTJ6D (Cyclosporine)
    • Publication Date:
      Date Created: 20191012 Date Completed: 20210528 Latest Revision: 20210528
    • Publication Date:
      20240105
    • Accession Number:
      10.1080/09537104.2019.1678121
    • Accession Number:
      31603012